Article Details

Fate Therapeutics (NASDAQ:FATE) Receives Sell (E+) Rating from Weiss Ratings

Retrieved on: 2025-10-09 17:55:49

Tags for this article:

Click the tags to see associated articles and topics

Fate Therapeutics (NASDAQ:FATE) Receives Sell (E+) Rating from Weiss Ratings. View article details on hiswai:

Excerpt

Acadian Asset Management LLC now owns 2,473,565 shares of the biopharmaceutical company's stock valued at $1,952,000 after purchasing an additional ...

Article found on: www.defenseworld.net

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo